Rehmann Capital Advisory Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.95M | Buy |
10,283
+3,282
| +47% | +$617K | 0.09% | 165 |
|
|
2026
Q1 | $1.38M | Buy |
7,001
+39
| +0.6% | +$7.52K | 0.07% | 193 |
|
|
2025
Q4 | $1.28M | Buy |
6,962
+1,297
| +23% | +$227K | 0.07% | 196 |
|
|
2025
Q3 | $869K | Buy |
5,665
+729
| +15% | +$110K | 0.05% | 256 |
|
|
2025
Q2 | $690K | Sell |
4,936
-709
| -13% | -$99.4K | 0.04% | 288 |
|
|
2025
Q1 | $830K | Buy |
5,645
+285
| +5% | +$41.2K | 0.05% | 253 |
|
|
2024
Q4 | $702K | Buy |
5,360
+346
| +7% | +$48.4K | 0.04% | 269 |
|
|
2024
Q3 | $788K | Buy |
5,014
+88
| +2% | +$14.2K | 0.05% | 249 |
|
|
2024
Q2 | $768K | Buy |
4,926
+797
| +19% | +$120K | 0.06% | 247 |
|
|
2024
Q1 | $560K | Buy |
4,129
+273
| +7% | +$36.1K | 0.04% | 297 |
|
|
2023
Q4 | $519K | Buy |
3,856
+1,245
| +48% | +$162K | 0.04% | 308 |
|
|
2023
Q3 | $354K | Sell |
2,611
-27
| -1% | -$3.69K | 0.03% | 365 |
|
|
2023
Q2 | $378K | Sell |
2,638
-127
| -5% | -$18.7K | 0.03% | 367 |
|
|
2023
Q1 | $384K | Buy |
2,765
+119
| +4% | +$16K | 0.04% | 359 |
|
|
2022
Q4 | $359K | Buy |
2,646
+21
| +0.8% | +$2.63K | 0.04% | 365 |
|
|
2022
Q3 | $288K | Buy |
2,625
+300
| +13% | +$38.1K | 0.03% | 391 |
|
|
2022
Q2 | $307K | Buy |
2,325
+426
| +22% | +$55.9K | 0.03% | 368 |
|
|
2022
Q1 | $252K | Sell |
1,899
-421
| -18% | -$50.5K | 0.02% | 445 |
|
|
2021
Q4 | $270K | Sell |
2,320
-152
| -6% | -$17.9K | 0.03% | 460 |
|
|
2021
Q3 | $297K | Buy |
+2,472
| New | +$288K | 0.03% | 440 |
|
|
2020
Q4 | – | Sell |
-2,228
| Closed | -$244K | – | 483 |
|
|
2020
Q3 | $244K | Buy |
2,228
+124
| +6% | +$13.8K | 0.03% | 364 |
|
|
2020
Q2 | $223K | Buy |
+2,104
| New | +$217K | 0.03% | 381 |
|
|
2019
Q3 | $150K | Buy |
1,687
+160
| +10% | +$13.9K | 0.02% | 365 |
|
|
2019
Q2 | $126K | Sell |
1,527
-42
| -3% | -$3.29K | 0.02% | 546 |
|
|
2019
Q1 | $127K | Buy |
1,569
+122
| +8% | +$9.62K | 0.02% | 526 |
|
|
2018
Q4 | $110K | Buy |
1,447
+168
| +13% | +$13.1K | 0.02% | 386 |
|
|
2018
Q3 | $101K | Hold |
1,279
| – | – | 0.01% | 585 |
|
|
2018
Q2 | $89.8K | Sell |
1,279
-273
| -18% | -$19.6K | 0.01% | 585 |
|
|
2018
Q1 | $109K | Buy |
+1,552
| New | +$108K | 0.02% | 520 |
|
Other funds holding AZN
EP
IA
Rehmann Capital Advisory Group's AZN Position: Q2 2026 in Review
Rehmann Capital Advisory Group increased its AstraZeneca (AZN) stake by 47% in Q2 2026, buying an estimated $617K and bringing the position to 10,283 shares worth $1.95M. The position accounts for 0.09% of the portfolio, ranked #165.
Rehmann Capital Advisory Group first reported a position in AZN in Q1 2018 and has held it in 29 quarters since. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Rehmann Capital Advisory Group held 10,283 shares of AstraZeneca worth $1.95M as of Q2 2026.
- Rehmann Capital Advisory Group bought 3,282 AstraZeneca shares in Q2 2026, an estimated $617K.
- AstraZeneca made up 0.09% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #165 holding.
- Rehmann Capital Advisory Group first reported a position in AstraZeneca in Q1 2018 and has held it in 29 quarters since.
- 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.